Home › Compare › VNTA vs JNJ

VNTA vs JNJ: Dividend Comparison 2026

VNTA yields 4987.53% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VNTA wins by $60726414423802.57M in total portfolio value
10 years
VNTA
VNTA
● Live price
4987.53%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$60726414423802.59M
Annual income
$58,422,163,401,288,310,000.00
Full VNTA calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — VNTA vs JNJ

📍 VNTA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVNTAJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VNTA + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
VNTA pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VNTA
Annual income on $10K today (after 15% tax)
$423,940.15/yr
After 10yr DRIP, annual income (after tax)
$49,658,838,891,095,065,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, VNTA beats the other by $49,658,838,891,095,065,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VNTA + JNJ for your $10,000?

VNTA: 50%JNJ: 50%
100% JNJ50/50100% VNTA
Portfolio after 10yr
$30363207211901.30M
Annual income
$29,211,081,700,644,155,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VNTA
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VNTA buys
0
JNJ buys
0
No recent congressional trades found for VNTA or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVNTAJNJ
Forward yield4987.53% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$60726414423802.59M ✓$20.0K
Annual income after 10y$58,422,163,401,288,310,000.00 ✓$827.78
Total dividends collected$60570499970588.68M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VNTA vs JNJ ($10,000, DRIP)

YearVNTA PortfolioVNTA Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$509,453$498,753.12$10,676$355.77+$498.8K → VNTA
2$24,291,968$23,746,853.30$11,407$389.39+$24.28M → VNTA
3$1,084,224,114$1,058,231,708.37$12,198$426.53+$1084.21M → VNTA
4$45,302,256,588$44,142,136,785.73$13,056$467.62+$45302.24M → VNTA
5$1,772,207,810,855$1,723,734,396,305.83$13,987$513.12+$1772207.80M → VNTA
6$64,916,695,091,411$63,020,432,733,796.11$14,998$563.56+$64916695.08M → VNTA
7$2,226,904,004,397,647$2,157,443,140,649,837.00$16,098$619.52+$2226904004.38M → VNTA
8$71,550,063,790,460,920$69,167,276,505,755,440.00$17,295$681.69+$71550063790.44M → VNTA
9$2,153,505,628,518,013,700$2,076,947,060,262,220,500.00$18,599$750.82+$2153505628518.00M → VNTA
10$60,726,414,423,802,585,000$58,422,163,401,288,310,000.00$20,022$827.78+$60726414423802.57M → VNTA

VNTA vs JNJ: Complete Analysis 2026

VNTA — Stock

Ventana Biotech, Inc., a development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. The company focuses in the areas of anti-obesity and related illnesses. The company holds rights for the formula for a medicament containing chewing gum with a composition of the extract of hoodia gordonii and 2-hydroxyoleic acid for the treatment of obesity, hypertension, and other metabolic disorders. The company develops appetite suppressant chewing gums, including the low dosage product for the over-the-counter market and the high dosage product for distribution by pharmacists. It intends to market low dosage product though drug and health food stores. The company was formerly known as Personalica, Inc. and changed its name to Ventana Biotech, Inc. in October 2008. Ventana Biotech, Inc. was founded in 1989 and is based in Butschwil, Switzerland.

Full VNTA Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this VNTA vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VNTA vs SCHDVNTA vs JEPIVNTA vs OVNTA vs KOVNTA vs MAINVNTA vs ABBVVNTA vs MRKVNTA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.